152 related articles for article (PubMed ID: 34256299)
1. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
Darney K; Lautz LS; Béchaux C; Wiecek W; Testai E; Amzal B; Dorne JLCM
Environ Int; 2021 Nov; 156():106760. PubMed ID: 34256299
[TBL] [Abstract][Full Text] [Related]
2. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
[TBL] [Abstract][Full Text] [Related]
3. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
4. The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
Quignot N; Wiecek W; Amzal B; Dorne JL
Arch Toxicol; 2019 Jan; 93(1):107-119. PubMed ID: 30298208
[TBL] [Abstract][Full Text] [Related]
5. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
7. A Computational Understanding of Inter-Individual Variability in CYP2D6 Activity to Investigate the Impact of Missense Mutations on Ochratoxin A Metabolism.
Dorne JLCM; Cirlini M; Louisse J; Pedroni L; Galaverna G; Dellafiora L
Toxins (Basel); 2022 Mar; 14(3):. PubMed ID: 35324704
[TBL] [Abstract][Full Text] [Related]
8. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
9. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors.
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2003 Feb; 41(2):225-45. PubMed ID: 12480299
[TBL] [Abstract][Full Text] [Related]
11. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
12. Bayesian meta-analysis of inter-phenotypic differences in human serum paraoxonase-1 activity for chemical risk assessment.
Darney K; Kasteel EEJ; Buratti FM; Turco L; Vichi S; Béchaux C; Roudot AC; Kramer NI; Testai E; Dorne JLCM; Di Consiglio E; Lautz LS
Environ Int; 2020 May; 138():105609. PubMed ID: 32114288
[TBL] [Abstract][Full Text] [Related]
13. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ
J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
[TBL] [Abstract][Full Text] [Related]
15. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
17. Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment.
Darney K; Turco L; Buratti FM; Di Consiglio E; Vichi S; Roudot AC; Béchaux C; Testai E; Dorne JLCM; Lautz LS
Food Chem Toxicol; 2020 Jun; 140():111305. PubMed ID: 32234423
[TBL] [Abstract][Full Text] [Related]
18. Human variability in glutathione-S-transferase activities, tissue distribution and major polymorphic variants: Meta-analysis and implication for chemical risk assessment.
Buratti FM; Darney K; Vichi S; Turco L; Di Consiglio E; Lautz LS; Béchaux C; Dorne JCM; Testai E
Toxicol Lett; 2021 Feb; 337():78-90. PubMed ID: 33189831
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
20. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
